TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier

As the first in a new class of non-opioid drugs, ω-Conotoxin MVIIA was approved for the management of severe chronic pains in patients who are unresponsive to opioid therapy. Unfortunately, clinical application of MVIIA is severely limited due to its poor ability to penetrate the blood-brain ba...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Shuo Yu, Yumeng Li, Jinqin Chen, Yue Zhang, Xinling Tao, Qiuyun Dai, Yutian Wang, Shupeng Li, Mingxin Dong
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2019-05-01
Serie:	Marine Drugs
Ämnen:	ziconotide TAT (the transactivator of transcription domain) peptide analgesics BBB (blood-brain barrier) penetration
Länkar:	https://www.mdpi.com/1660-3397/17/5/286
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!